Bernstein Downgrades Summit Therapeutics to Underperform
Bernstein has downgraded Summit Therapeutics from 'Market Perform' to 'Underperform' with a price target of $8.30.
Stocks · News reference
Summit Therapeutics announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding the Biologics License Application (BLA) for ivonescimab.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Bernstein has downgraded Summit Therapeutics from 'Market Perform' to 'Underperform' with a price target of $8.30.
Filed: 2026-11-18 AccNo: 0001599298-26-000094 Size: 1 MB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Summit Therapeutics has launched the HARMONi-10 global Phase III clinical trial to evaluate ivonescimab as a consolidation therapy for patients with unresectable Stage III non-small cell lung cancer.
XBI and IBB lagged SPY and QQQ as two FDA decisions and fresh Alzheimer's and obesity-drug data put biotech ETFs in focus.